Find Funding Opportunities

Extension Expiration Date PAR-09-065, NINDS Career Development Award Promote Diversity Neuroscience Research K01) Notice Number: NOT-NS-12-001 Key Dates Release Date: November 3, 2011 Related Notices PAR-09-065 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice extends expiration date Funding Opportunity Announcement FOA) PAR-09-065, NINDS Career Development Award Promote Diversity Neuroscience Research K01). new expiration date PAR-09-065 May 8, 2012. other aspects these FOAs remain same.  Please review incorporate updates relating this announcement; updates located Part Overview Information. Inquiries Please direct inquiries to: Michelle D. Jones-London, Ph.D. Office Training, Career Development Workforce Diversity National Institute Neurological Disorders Stroke NSC 2181 6001 Executive Blvd. Bethesda, MD 20892 Rockville, MD 20852 express/courier service) Telephone: 301) 451-7966 Email: jonesmiche@ninds.nih.gov

Notice Revision RFA-RM-11-008, Human Heredity Health Africa H3Africa): Collaborative Centers U54) Notice Number: NOT-RM-12-002 Key Dates Release Date: October 14, 2011 Issued National Institutes Health NIH) National Human Genome Research Institute NHGRI) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) Office AIDs Research OAR) nbsp; Fogarty International Center FIC) Office Strategic Coordination Common Fund)       Purpose purpose this Notice to revise wording three passages RFA-RM-11-008: READS: Section IV, 2. Page Limitations quot;The Research Strategy section each component the scientific the collaborative center limited 12 pages length.  there an administrative core, is limited 6 pages length."   SHOULD READ: quot;The Research Strategy section each component the scientific plan the collaborative center limited 12 pages length.  Administration Management Component, also limited 12 pages length. IEARD request also limited 12 pages." READS: Section IV, 2. Administration Management:  quot;If desired, activities be included a separate Administrative Core."  SHOULD READ: quot;These activities be included a separate Administration Management Component.  Additionally IEARD request limited 12 pages length." READS: Section IV, 2. Under Collaborations. quot;If appropriate, of collaborating components be management core." SHOULD READ: Section IV, 2. Under Collaborations. appropriate, of collaborating components be Administration Management Component.” READS: Section I, Part 2, B under Implementation the Objectives H3Africa, Interactions other programs.  quot;The H3Africa requires collaborative centers form partnerships Africa institutions have ongoing studies offer infrastructure the research focus area are currently conducting genomics environmental research." SHOULD READ: quot;The H3Africa requires collaborative centers form partnerships Africa institutions have ongoing studies offer infrastructure the research focus area." Inquiries Please direct inquiries to: Jane L. Peterson, Ph.D. National Human Genome Research Institute National Institutes Health 5635 Fishers Lane, Suite 4076, MSC 9305 Bethesda, MD 20892-9305 Phone: 301 496 7531 Fax: 301 480 2770 Email: Jane_Peterson@nih.gov H3Africa website: http://H3Africa.org

Notice Revision RFA-RM-11-009, Human Health Heredity Africa H3Africa): Research Projects U01) Notice Number: NOT-RM-12-003 Key Dates Release Date: October 14, 2011 Issued National Institutes Health NIH) National Human Genome Research Institute NHGRI) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) Office AIDs Research OAR)  Fogarty International Center FIC) Office Strategic Coordination Common Fund) Purpose purpose this Notice to revise wording two passages RFA-RM-11-009: READS: Part 2, Section I, Purpose.  quot;The current FOA a call applications new established genomicists propose establish collaboration between independently funded H3Africa genomics/genetics project an ongoing, funded project does currently a genomics focus.” SHOULD READ: quot;The current FOA a call applications new established genomicists propose establish genomics/genetics research project collaborate an ongoing, funded project either does currently a genomics focus where augmentation expansion a current genomics/genetics component enable funded work accomplish larger, complete genomics study would otherwise possible.” READS: Part 2, Section I, Research Objectives. quot; objective this FOA to solicit applications establish independent H3Africa Research Projects will collaborate ongoing grants, cooperative agreements, contracts, awards the U.S. government USG) e.g. CDC, DOD, HRSA, NIH, USAID, others) non-USG funders e.g., Wellcome Trust, Doris Duke Charitable Foundation, Bill amp; Melinda Gates Foundation, others) add genomics-based approach the study a chronic infectious disease an on-going funded study does currently a genetics component."  SHOULD READ: quot; objective this FOA to solicit applications establish independent H3Africa Research Projects will collaborate ongoing grants, cooperative agreements, contracts, awards the U.S. government USG) e.g. CDC, DOD, HRSA, NIH, USAID, others) non-USG funders e.g., Wellcome Trust, Doris Duke Charitable Foundation, Bill amp; Melinda Gates Foundation, others) add genomics-based approach the study a chronic infectious disease an on-going funded study does currently a genetics component to augment expand current genomics/genetics component enable funded work accomplish larger, complete genomics study would otherwise possible." READS: quot;The Office Strategic Coordination OSC), NHGRI, NIDA, NINDS, NICHD, OAR reserve right withhold funding curtail study an individual award) the event a) substantive changes the agreed-upon work scope which OSC, NHGRI, NIDA, NINDS, NICHD, OAR cannot concur, b) human subject ethical issues may dictate premature termination." SHOULD READ:  "The Office Strategic Coordination OSC), NHGRI, NIDA, NINDS, NICHD, OAR reserve right withhold funding curtail study an individual award) the event a) substantive changes the agreed-upon work scope which OSC, NHGRI, NIDA, NINDS, NICHD, OAR cannot concur, b) human subject ethical issues may dictate premature termination.  term the H3Africa Research Grant award be five years, unless funded grant which is collaborating terminated prior the end the H3Africa Research Grant's funding period.  that case, Office Strategic Coordination OSC), NHGRI, NIDA, NINDS, NICHD, OAR reserve right consider current status the H3Africa Research grant, progress other factors may relevant order make decision to whether not H3Africa Research Grant be terminated prior its full term." Inquiries Please direct inquiries to: Jane L. Peterson, Ph.D. National Human Genome Research Institute National Institutes Health 5635 Fishers Lane, Suite 4076, MSC 9305 Bethesda, MD 20892-9305 Phone: 301 496 7531 Fax: 301 480 2770 Email: Jane_Peterson@nih.gov H3Africa website: http://H3Africa.org

Notice Response Date Extension Request Information Soliciting Input Creating Data Management Resource the Parkinson's Disease Biomarkers Program NOT-NS-11-027) Notice Number: NOT-NS-11-031 Key Dates Release Date: September 30, 2011 Extended Response Date: October 7, 2011   Related Notices NOT-NS-11-027 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential responders NOT-NS-11-027 the response date submitting information been extended. new response date October 7, 2011.  is time-sensitive RFI designed seek public comment considerations the development the Data Management Resource DMR) the Parkinson's Disease Biomarkers Program PDBP).  Responses this RFI be analyzed considered planning designing strategies establishment the DMR for data coordination, integration, sharing across PDBP program. Responses must submitted electronically using web-based form at: http://www.ninds.nih.gov/dmr) later October 7, 2011. Inquiries Please direct inquiries to: Margaret Sutherland, PhD Program Director, Neurodegeneration Cluster NINDS / NIH 6001 Executive Blvd., Rm 2222 Bethesda, MD 20892 Phone: 301-496-5680 Fax: 301-480-1080 E-mail: sutherlandm@ninds.nih.gov

Pre-application Meeting RFA-NS-12-006 – Exploratory/Planning Grant Program Disease Modification Prevention the Epilepsies P20) Notice Number: NOT-NS-11-030 Key Dates Release Date:  September 27, 2011 Pre-Application Meeting Date: October 12, 2011 Related Notices RFA-NS-12-006 Issued National Institute Neurological Disorders Stroke NINDS)) Purpose National Institute Neurological Disorders Stroke NINDS) hold pre-application meeting regarding RFA-NS-12-006, which prospective applicants invited. is intended explain goals objectives this initiative answer questions prospective applicants. Participation this meeting neither required nor necessary a successful application. Meeting Details Title: Pre-application Meeting RFA-NS-12-006 When: Wednesday, October 12, 2010, 2:00-3:00 PM Time Zone: GMT - 05:00) Eastern Time US Canada) Website: https://webmeeting.nih.gov/rfa-ns-12-006/ Conference number US Participants): 1-800-591-2259 Participant Code: 401430 Non-US participants should email contact listed below call-in information your specific location be provided. Please email questions advance, wished, the below contact. While effort be to include questions, is possible not will addressed during meeting due time constraints. Inquiries Please direct inquiries to: Brandy Fureman, PhD National Institute Neurological Disorders Stroke 6001 Executive Blvd Room 2138 Bethesda MD 20892 Telephone: 301-496-1917 Fax: 301-502-1501 Email: furemanb@ninds.nih.gov

Modified Receipt Decision Process PAR-11-344 X01) Notice Number: NOT-NS-11-025 Key Dates Release Date: September 21, 2011 Related Notices PAR-11-344)   Issued National Institute Neurological Disorders Stroke NINDS)) Purpose purpose this Notice to inform community the National Institutes Health implementing alternate plan receipt review X01 applications seeking access the NeuroNEXT infrastructure conduct clinical trials neurological diseases: PAR-11-344, NeuroNEXT Infrastructure Resource Access X01). alternate receipt review plan not applicable PAR-11-343, NeuroNEXT Clinical Trials U01) PAR-11-345, NeuroNext Small Business Innovation Clinical Trials U44). Interested parties should look those announcements the applicable receipt dates. Processing Review Schedule: Applications PAR-11-344, NeuroNEXT Infrastructure Resource Access X01), be submitted any time will reviewed later 120 days after receipt.  Because the need assign Advisory Council date, following schedule be followed.  However, applications be moved earlier Councils timing permits.  Schedule Assignment Advisory Council Rounds Council Round Receipt Window November 13 - March 12 October March 13 - July 12 January July 13 - November 12 Inquiries D. Elizabeth McNeil, MD MSc 6001 Executive Boulevard, MSC 9520 Rockville, MD 20852 Phone: 301-496-9135 Fax: 301-480-1080 Email: mcneilde@ninds.nih.gov 

Notice Response Date Extension Request Information Soliciting Input Enhancing Diversity Academic Research Institutions NOT-NS-11-021) Notice Number: NOT-NS-11-029 Key Dates Release Date: September 16, 2011 Extended Response Date: October 28, 2011   Related Notices NOT-NS-11-021 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential responders NOT-NS-11-021 the response date submitting information been extended. new response date October 28, 2011. is time-sensitive RFI designed improve strategies the enhancement diversity the neuroscience neurology research workforce. Responses this RFI be analyzed considered planning development future initiatives. Responses must submitted electronically using web-based form at:  (http://www.ninds.nih.gov/ospd-rfi/) later October 28, 2011.  Inquiries Please direct inquiries to: Courtney Ferrell Aklin, Ph.D. Office Special Programs Diversity National Institute Neurological Disorders Stroke 6001 Executive Blvd, room 2149 Bethesda, MD 20892 Telephone: 301-496-3102 Courtney.ferrellaklin@nih.gov    

Meetings Introduce Network Excellence Neuroscience Clinical Trials NeuroNEXT) Notice Number: NOT-NS-11-028 Key Dates Release Date: September 9, 2011   Issued National Institute Neurological Disorders Stroke NINDS) Purpose Network Excellence Neuroscience Clinical Trials NeuroNEXT) designed increase efficiency clinical trials, facilitate patient recruitment retention, increase quality neuroscience clinical trials, to enable public-private partnerships. network include multiple Clinical Sites, Clinical Coordinating Center CCC), one Data Coordinating Center DCC). clinical research network provide robust, standardized, accessible infrastructure facilitate rapid development implementation protocols neurological disorders affecting adult and/or pediatric populations. selected infrastructure sites be posted the NeuroNEXT website early October www.ninds.nih.gov/NeuroNEXT). Since of NeuroNEXT goals to facilitate promote public-private partnerships, NINDS hold targeted meetings introduce network potential partners industry advocacy/patient groups. Interested parties participate person, via teleconference and/or via weblink. Weblink access be available the first 20 requestors. Persons are interested weblink access should contact Dr. McNeil indicated below. Meeting introduce NeuroNEXT Industry: October 7, 2011 10:00 am - 11:00 am EDT) NINDS Neuroscience Center, Room 2172 6001 Executive Blvd., Bethesda, MD  20892 Teleconference number 888-810-8161, passcode 34632 Meeting introduce NeuroNEXT Advocacy/Patient Groups: October 14, 2011 11:00 am - 12:00 pm EDT) NINDS Neuroscience Center, Room 2172 6001 Executive Blvd., Bethesda, MD  20892 Teleconference number 888-603-7919, passcode 68848 Inquiries Please direct inquiries to: D. Elizabeth McNeil, MD MSc NINDS Telephone: 301-496-9135 mcneilde@ninds.nih.gov www.ninds.nih.gov/NeuroNEXT

NINDS Request Information RFI) Creating Data Management Resource the Parkinson's Disease Biomarkers Program Notice Number: NOT-NS-11-027 Update: following update relating this announcement been issued: September 30, 2011 - Notice NOT-NS-11-031. Notice extend response date. Key Dates Release Date: September 1, 2011 Response Date: assure consideration, comments must received Extended October 7, 2011 per NOT-NS-11-031), Originally September 30, 2011    Related Notices NOT-NS-11-020 Issued National Institute Neurological Disorders Stroke NINDS) Purpose stated the recent Notice NOT-NS-11-020), NINDS intends establish Parkinson’s Disease Biomarkers Program PDBP).  Initially, PDBP have three major components: 1) Discovery projects identify promising biomarkers; 2) resource the banking sharing existing prospective biological samples; 3) Data Management Resource DMR).  goal this RFI to seek public comment considerations the development the Data Management Resource the Parkinson's Disease Biomarkers Program PDBP).  resource receive, process, distribute standardized clinical, imaging, biological, molecular data discovery other Parkinson’s biomarkers projects.  Both positive negative data be included the DMR. Information obtained via RFI help NINDS designing strategies establishment the DMR for data coordination, integration, sharing across PDBP program. Background Recently, has considerable progress our understanding the biology Parkinson’s disease.  However, inadequate measures disease progression, limited ability detect neurodegeneration prior the onset motor signs, the lack assays measure target engagement potential therapeutics currently impede therapy development.  overcome obstacles, NINDS intends establish Parkinson’s Disease Biomarkers Program PDBP) stated above in NOT-NS-11-020).  goal this program to facilitate development neuroprotective agents slow halt progression Parkinson’s disease.  providing shared, high quality resources, PDBP program coordinate efforts multiple stakeholders.  will facilitate both clinical laboratory-based discovery projects designed lead the validation candidate markers pre-symptomatic diagnosis monitoring disease progression. markers ultimately critical designing effective Phase II III clinical trials.  Information Requested Data Management RFI invites input the broader biomedical research community innovative strategies practices have proven successful Data Management projects requiring receipt, maintenance, storage, analysis, distribution a variety data types clinical, genetic, imaging, molecular, etc.) formats.  input include following concerns: 1.  Define optimal strategy collecting broadly disseminating de-identified clinical imaging data, any. 2.  key factors consider coordinating data multiple studies through single data management resource, any.  3.  level type quality control should adopted across datasets. 4.  Describe most common problem experienced data users accessing analyzing shared data provided through data management resource. 5.  Describe key features assure patient privacy concerns addressed broadly sharing de-identified clinical data. Data Utilization RFI also invites input investigators have accessed utilized data broadly available data resources.  input include following concerns: 1.  Identify data management resource exemplifies ease use access the user, any. 2.  limitations assessing analyzing imaging data longitudinal studies utilize data management coordinating center data access, any. 3.  Assuming policies in place data acquisition, describe most common roadblocks data access utilization data distributed a data management coordinating center. General Information Note: of following fields optional. Proprietary, classified, confidential, sensitive information should be included your response.  1.  Please identify nature your interest the area data management services Parkinson's disease biomarkers i.e. you biomedical clinical researcher, member an advocacy community group, other?). 2.  you a member a particular advocacy professional organization, please indicate name the organization. 3.  Please indicate main area research interest. 4.  name. 5.  email address. Responses Responses must submitted electronically using web-based form http://www.ninds.nih.gov/dmr) will accepted through September 30, 2011.  Any personal identifiers e.g., names, addresses, email addresses, etc.) be removed responses compiled.  Proprietary, classified, confidential, sensitive information should be included your response. Replies individual questions optional, the site permit anonymous responses. information provided be analyzed may appear various reports. Request Information RFI) for planning purposes only is a solicitation applications an obligation the part the United States U.S.) Government provide support any ideas identified response it.  Please note the U.S. Government not pay the preparation any comment submitted for use that comment. Inquiries Please direct inquiries to: Margaret Sutherland, PhD Program Director, Neurodegeneration Cluster NINDS / NIH 6001 Executive Blvd., Rm 2222 Bethesda, MD 20892 Phone: 301-496-5680 Fax: 301-480-1080 E-mail: sutherlandm@ninds.nih.gov

Extension Expiration Date PA-08-191: Research Supplements Promote Re-Entry Biomedical Behavioral Research Careers Notice Number: NOT-OD-11-112 Key Dates Release Date: September 1, 2011 Issued Office Research Women’s Health ORWH) National Cancer Institute NCI) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Library Medicine NLM) John E. Fogarty International Center FIC) National Center Complementary Alternative Medicine NCCAM) National Center Research Resources NCRR) Office Dietary Supplements ODS) Purpose Notice extends expiration date the Funding Opportunity Announcement FOA) PA-08-191: Research Supplements Promote Re-Entry Biomedical Behavioral Research Careers.  new expiration date this FOA September 30, 2012. Before submitting application a research supplement, applicants strongly encouraged contact program official discuss program: http://grants.nih.gov/grants/guide/contacts/PA-08-191_Contact.htm other aspects the FOA remain unchanged. Inquiries Please direct inquiries to: Joyce Rudick Office Research Women’s Health National Institutes Health Email: joyce.rudick@nih.hhs.gov Henry Khachaturian, Ph.D. Office Extramural Research National Institutes Health Email: NIHTrain@mail.nih.gov